The past year is set to be a milestone year for China's pharmaceutical regulatory reform as the newly formed National Medical Products Administration (NMPA) continues to aggressively cut back on red tape for new drug approvals.1 In November 2018, in an unprecedented regulatory action, NMPA called on global pharmaceutical companies to bring 48 innovative drugs to China. 2 These drug products are indicated for rare diseases or other life-threatening diseases and have already been approved in the U.S., EU, or Japan. Significantly, once the drug sponsors can submit data demonstrating no ethnic differences for the efficacy, the drug products can be approved without any additional clinical trials in China. 3 In December 2018, AstraZeneca and its China partner, FibroGen, received NMPA's market authorization for their roxadustat, a firstin-class anemia drug for kidney patients. 4 This is the first time NMPA approved an innovative drug product from a global pharmaceutical company before any other country in the world. Notably, at a press conference in February 2019, senior officials from NMPA told reporters that a total of 18 new cancer drugs were approved in China in 2018, which marks a 157% increase in comparison with 2017. 5 Further, the average review time for these cancer drugs in 2018 was 12 months, down from 24 months prior to 2018.
With the opportunity to gain access to the Chinese market presenting itself like never before, two recent initiatives by the Chinese government are worthy of noting because one of them will have significant ramifications on drug pricing for generic drugs and the other presents unique operational challenges for global pharmaceutical companies. Specifically, in December 2018, China implemented a pilot centralized drug procurement program that aims to substantially reduce prices for generic drugs. Also in December 2018, NMPA published a new regulation for its overseas inspection program, under which serious violations of Chinese cGMP regulations can lead to the suspension of drug sales or even product recalls in China. A more detailed summary and assessment of these two programs follows.
The Pilot Centralized Drug Procurement Program
"4+7" Program Slashes the Generic Drug Prices by Half
While China has a national public healthcare system and the public hospitals owned by the government are the major healthcare providers, historically, drug procurement was conducted at province level. In December 2018, a new pilot centralized drug procurement program fundamentally changed how generic drugs are priced in China. It is noteworthy that the program was established by an agency called the Central Comprehensively Deepening Reforms Commission, which is directly led by the Politburo of the Communist Party of China. The program is also commonly referred to as the "4+7 Program" in China because it covers 4 municipalities including Beijing, Tianjin, Shanghai, Chongqing and 7 other cities including Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu, and Xi'an. Under the 4+7 Program, every pharmaceutical company has the opportunity to submit bids for generic drugs and the government will award a contract to the winner, who will be guaranteed a sale volume of 60-70% of the total market in public hospitals in the 11 major cities for a year. The successful bids are selected based on the following criteria: 6
- Three or more bidders for the same generic drug product: the lowest bidder will automatically be awarded the contract.
- Two bidders: the lower bidder will be chosen for a second round of negotiation with the procurement office. The average discount rates from other generic drugs offered will be used as a reference for the negotiation.
- Only one bidder: the average discount rates from other generic drugs offered will be used as a reference for the negotiation.
After the first public bidding, which took place on-site in Shanghai, generic drug manufacturers were awarded contracts for 25 generic drugs with guaranteed sales volume in the 11 major cities in China.7 The average discount rate from the winning bid is 52%, when compared to the lowest drug prices in these 11 major cities in 2017. The most controversial element of the 4+7 Program is that the only determining factor for a successful bid is the price. It is therefore not surprising that while many global pharmaceutical companies participated in the bidding process, only two successful bids came from pharmaceutical manufacturers not entirely owned by a Chinese entity—Gefitinib tablets from AstraZeneca AB and Fusinopril tablets from Sino-American Shanghai Squibb Pharmaceuticals Co., Ltd. 8
Implications for Drug Reimbursement
While it is still unclear at this point when and whether the 4+7 Program will be rolled out nationwide, it already has an immediate national impact on generic drug prices. Significant news broke on March 5th that the National Healthcare Security Administration, the country's top agency in charge of the public healthcare system, announced that the reimbursement for drugs under the public healthcare plan nationwide will also be tied to the drug prices from the winning bids under the 4+7 Program. According to the "Opinions of the National Healthcare Security Administration on Supporting Measures Concerning Medical Insurance for the Pilot Program for Conducting Centralized Procurement and Use of Drugs by the State,"9 the reimbursement rate under the national healthcare plan will be determined as follows:
- When the drugs are priced twice as much as the winning bid under the 4+7 Program: the 2019 reimbursement rate should be no less than 30% lower than the original rate, and the 2020 and 2021 reimbursement rates should be based on the drug prices of the winning bids under the 4+7 Program.
- When the drugs are priced slightly above and no more than twice as much of the winning bid under the 4+7 Program, the reimbursement rate should be based on the drug prices of the winning bids.
- If the drugs are priced lower than the winning bid, the reimbursement rate should be based on the actual drug price.
Since Chinese patients will be responsible for any price difference above the reimbursement rate, the 4+7 Program's impact will go way beyond the public hospitals in 11 major cities. Indeed, several drug manufacturers have recently announced that they will voluntarily lower their prices to be close or even lower than the winning bids under the 4+7 Program.10 As global pharmaceutical companies look to do business in China, the implementation of the 4+7 Program will undoubtedly impact strategies on how to commercialize generic drug products and how to best compete in a bidding war with a domestic Chinese drug manufacturer.
To view the full article click here
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.